Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ElectromedELMD +1.14%90 EV-to-EBIT is 24.45 as of Aug. 02, 2026, which is 27% above its 10-year median of 19.28. GuruFocus rates ELMD with a GF Score™ of 90/100 and a GF Value™ of $25.49 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 470 Medical Devices & Instruments companies, Electromed ranks worse than 64.89% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Electromed's Enterprise Value for the quarter that ended in Mar. 2026 was $176.85 Mil.
Electromed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Electromed EV-to-EBIT Related Terms
Electromed EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Electromed's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Electromed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Electromed EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Electromed's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Electromed's EV-to-EBIT falls into.
Electromed's current Enterprise Value is $320.26 Mil.
Electromed's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Electromed (ELMD) has a EV-to-EBIT of 24.45 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Electromed and its competitors. This is 27% above median its historical median of 19.28. Over the past decade, Electromed's EV-to-EBIT has ranged from 10.09 to 41.22. According to the industry distribution chart, Electromed ranks #305 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 64.9%.
Is Electromed's EV-to-EBIT too high?
Electromed's current EV-to-EBIT of 24.45 is 27% above median its 10-year median of 19.28. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 41.22. The Medical Devices & Instruments industry median EV-to-EBIT is 18.85. Electromed's value of 24.45 is 29.7% above this industry median. Based on the distribution chart, Electromed ranks #305 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Electromed has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Electromed's EV-to-EBIT compare to LAB and CV?
According to the Medical Devices & Instruments industry distribution chart, Electromed ranks #305 out of 470 companies for EV-to-EBIT. This places Electromed in the lower half of its industry. The industry median EV-to-EBIT is 18.85. Electromed's value of 24.45 is 29.7% above this benchmark. Historically, Electromed's own EV-to-EBIT has ranged from 10.09 to 41.22 over the past decade. While the company's 10-year median is 19.28 vs. the industry median of 18.85, Electromed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.85, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Electromed's current EV-to-EBIT of 24.45 is 29.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Electromed and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Electromed's current EV-to-EBIT is 24.45, which is 27% above median its own 10-year median of 19.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Electromed stock overvalued right now?
Based on GuruFocus' analysis, Electromed (ELMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.49, compared to a current price of $40.73 — trading 59.8% above its estimated fair value. The current EV-to-EBIT is 24.45, which is 27% above median its 10-year median of 19.28 and 29.7% above the Medical Devices & Instruments industry median of 18.85. Electromed's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Electromed (ELMD), the current EV-to-EBIT is 24.45 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Electromed (ELMD) Overvalued in 2026?
Based on GuruFocus' analysis, Electromed stock appears to be overvalued.
The current stock price of $40.73 is trading 59.8% above its estimated GF Value™ of $25.49.
GuruFocus considers Electromed to be Significantly Overvalued.
Key valuation signals for ELMD:
EV-to-EBIT: 24.45 (27% above median its 10-year median of 19.28)
GF Value™: $25.49 vs. price of $40.73 (59.8% above fair value)
Industry Position: 29.7% above the Medical Devices & Instruments median (#305 of 470)
No single metric tells the full story. See the ELMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
90GF Score
Get the complete analysis for ELMD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELMD has been successfully added to your 
